EcoDrugPlus

Purinergic Receptor P2y2, Tandem Duplicate 3

Ensembl ID : ENSDARG00000104425
Gene Symbol: P2RY2.3
5 Cross references
195 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSDARG00000006677
Gene Symbol: RIPK1L
21 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSDARG00000056704
Gene Symbol: RAMP1
7 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Regulatory Associated Protein Of Mtor, Complex 1

Ensembl ID : ENSDARG00000098726
Gene Symbol: RPTOR
20 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSDARG00000041858
Gene Symbol: REN
3 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSDARG00000055305
Gene Symbol: RET
10 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Gamma A

Ensembl ID : ENSDARG00000034117
Gene Symbol: RARGA
7 Enzyme and pathways 5 Cross references
326 Possible Orthologues:

Retinoic Acid Receptor, Gamma B

Ensembl ID : ENSDARG00000054003
Gene Symbol: RARGB
5 Cross references
363 Possible Orthologues:

Retinoid X Receptor, Alpha A

Ensembl ID : ENSDARG00000057737
Gene Symbol: RXRAA
37 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Retinoid X Receptor, Alpha B

Ensembl ID : ENSDARG00000035127
Gene Symbol: RXRAB
5 Cross references
182 Possible Orthologues:

Retinoid X Receptor, Beta B

Ensembl ID : ENSDARG00000002006
Gene Symbol: RXRBB
5 Cross references
215 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSDARG00000017500
Gene Symbol: ROCK2A
17 Enzyme and pathways 5 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).